Altheia Science is founded in 2017, operates from its headquarter in Via Enrico Besana, 7 Milano, Lombardia 20122, IT. The company operates in the Hospitals & Healthcare, Medical Practices sector. Currently, Altheia Science is a international company

Altheia Science specializes in Modulation of PD-L1 expression at the molecular and protein level, Advanced treatments for autoimmune diseases, Advanced treatments for cancer, Lentiviral vector-based engineering, Hematopoietic stem cell engineering, and offers services including Therapeutic tools for autoimmune diseases, Therapeutic tools for cancer, and First-in-class molecules controlling the PD-L1 pathway.